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A B ST R AC T 
 
 
Duodenal carcinoids are rare tumours of the small intestine with 
heterogenous clinical and pathological characteristics. The long-term 
prognosis is very good if discovered in the early stages. We present 
the case of a patient with a non-functional duodenal carcinoid tumour 
discovered incidentally during an upper gastrointestinal endoscopy. 
The diagnosis was confirmed through immunohistochemistry. 
Treatment consisted of the endoscopic resection of the tumour and 
the surveillance of the patient for the following 2 years, with no signs 
of recurrence. We have conducted a literature review regarding the 
clinical manifestations, diagnosis, treatment, and follow-up of 
patients with this type of tumours. 
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Introduction  
Carcinoid tumours arise from enterochromaffin cells 
of the aerodigestive tract. They are also known as low or 
intermediate grade well-differentiated neuroendocrine 
tumours (NETs). The incidence rates of carcinoid tumours 
has risen over time from 1.09:100000 (1973) to 
6.98:100000 (2012). This increase is partly explained by 
increased accessibility to endoscopic procedures and 
imaging techniques, particularly computed tomography 
(CT), which allow early detection in asymptomatic 
patients [1]. 
Carcinoid tumours with a primarily duodenal 
location represent less than 2% of the total number of 
carcinoid gastro-intestinal tumours, accounting for the 
lack of available data regarding these tumours in the 
literature [2]. 
Case Report 
We present the case of a 54-year-old male patient with 
a history of gastro-esophageal reflux disease (GERD) 
 
treated with prokinetic and proton pump inhibitor (PPI) 
therapy, returning for a routine follow-up consultation. 
Because the patient was still presenting persistent 
heartburn and bitter taste in the morning despite optimal 
medical treatment, we decided to perform an upper 
gastrointestinal endoscopy (UGE). 
The UGE revealed a 5 mm sessile polyp on the 
posterior wall of the duodenal bulb (Figure 1), followed 
by endoscopic polypectomy. The histopathological 
examination revealed several small solid nests on the 
lamina propria. These had uniform appearance, were well 
delineated, and consisted of round cells with granular 
eosinophilic cytoplasm in moderate quantities, as well as 
round normal and hyperchromatic nuclei, with no 
significant atypia, with an appearance highly  
suggestive of a neuroendocrine tumour (Figure 2). 
Immunohistochemical staining (IHC) tested negative for 
CKAE1/AE3 and positive for chromogranin (Figure 3) 
and CD56, with a KI-67% index less than 2%. These 
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results confirmed the diagnosis of a well-differentiated 
(G1) duodenal neuroendocrine tumour. 
 
Figure. 1. Upper gastrointestinal endoscopy showing 
the 5 mm sessile polyp on the posterior wall of the 
duodenal bulb. 
 
Figure 2. Microscopic examination of the resected 
piece, H&E, x10. Solid nests of neuroendocrine cells 
in the duodenal lamina propria. 
 
Figure 3. Immunohistochemical staining, x20. 
Tumour cells diffusely positive for chromogranin 
(x20). 
The serum concentration of chromogranin A (CrA) 
was within normal limits, with a value of 19.160 ng/ml. 
According to the consensus published by ENETS, the 
determination of other specific biological markers 
(gastrin, somatostatin, urinary 5-hydroxyindoleacetic acid 
(5-HIAA) is only recommended when functional 
syndromes are present, the most common being Zollinger-
Ellison (ZES) syndrome and carcinoid syndrome [3]. 
A contrast CT scan of the abdomen and pelvis was 
performed which did not reveal any other tumours nor 
regional or distant lymph node involvement. 
The patient’s final diagnosis was that of a well 
differentiated (G1) duodenal neuroendocrine tumour pT1 
cN0M0 and gastro-esophageal reflux disease (GERD). 
The treatment recommended for GERD was PPI 
therapy, while the treatment recommended for the 
carcinoid tumour following its resection was periodic 
surveillance. The follow-up of the patient was conducted 
according to the ENETS guideline at 6 months, 1 year, 
and 2 years [3]. Both biological and endoscopic follow-
ups were conducted, without revealing any signs of 
recurrence.  
We appreciate that the medium and long-term prognosis 
is favourable, considering the small size of the primary 
tumour (5 mm), its location in the duodenal mucosa, the 
normal values of chromogranin A, the high degree of 
differentiation (G1), the complete endoscopic resection, the 
absence of liver metastases, and the favourable evolution 
during the first two years of follow-up. 
The case we are presenting is one of the few reported 
in the literature of non-secreting NETs located in the 
duodenum, discovered accidentally and very early on. 
Jayarama et al. reported on the incidental discovery of 
two synchronous carcinoid tumours – one gastric and one 
duodenal [4]. There are two other reported cases of 
duodenal NETs discovered incidentally during a routine 
endoscopic examination [5, 6].  
Several observational studies have characterized these 
tumours. The largest study included 59 patients with 
duodenal carcinoid tumours, of which only 39 were non-
secreting [7]. Considering the heterogeneity of these 
tumours as well as the small number of studies available, 
at this time we cannot draw precise conclusions regarding 
the biological behaviour of well-differentiated, non-
periampullary, non-secreting duodenal neuroendocrine 
tumours, as in the case of our patient. 
Discussions 
Carcinoid tumours are a heterogenous group of 
tumours with varying behaviours depending on their 
location [8]. They are most frequently located in the 
gastro-intestinal (55%) and bronchopulmonary tracts 
(30%). Within the gastro-intestinal tract, the most 
frequent location is the small intestine (45%), followed by 
the appendix, colon, and stomach [2]. Although carcinoid 
tumours are relatively rare, they are the most frequent 
malignant tumours of the small intestine (44%). Tumours 
with a primarily duodenal location represent less than 2% 
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of the total number of well-differentiated gastro-intestinal 
neuroendocrine tumours. These are usually solitary 
lesions of small dimensions – 75% being under 2 cm. 
They are most frequently located in the first and second 
part of the duodenum (approximately 90%) [9]. 
Periampullary tumours are a special category, as studies 
have shown that they exhibit a different behaviour, 
leading some authors to suggest they be considered a 
separate entity [3]. 
There are five clinico-pathological types of duodenal 
neuroendocrine tumours described in the literature. In 
order of frequency, these are: gastrinomas, 
somatostatinomas, non-functional tumours, gangliocytic 
paragangliomas, and poorly differentiated tumours [10]. 
Most duodenal neuroendocrine tumours are restricted to 
the mucosa and submucosa. However, 40-60% of cases 
present regional lymph node involvement, while 
metastatic disease is present in approximately 10% of 
cases, with the most frequent metastatic site being the 
liver [3,10]. 
Usually, the clinical presentation is non-specific. The 
most commonly described symptoms are abdominal pain, 
nausea, vomiting, and diarrhea. Obstructive jaundice may 
appear in the case of periampullary tumours. A small 
proportion of patients present functional syndromes such 
as Zollinger-Ellison syndrome (ZES) or carcinoid 
syndrome. ZES associated with duodenal NETs may 
appear in relation to both sporadic tumours as well as part 
of the MEN1 syndrome, in which case there are usually 
multiple lesions. The carcinoid syndrome appears almost 
exclusively in the case of metastatic disease [10]. Only 
one case has been described in the literature referencing 
the presence of carcinoid syndrome in the absence of 
metastases [11]. 
The diagnosis is established through histopathological 
and immunohistochemical (IHC) examinations. 
Chromogranin, synaptophysin, PGP 9.5, and/or CD56 are 
the most sensitive and specific markers in the diagnosis of 
neuroendocrine tumours [12]. Studies show that 75-100% 
of duodenal carcinoids test positive for CrA, 80-100% for 
NSE, and 91% for Leu-7 [13,14]. In general, the most 
sensitive methods for locating neuroendocrine tumours 
are CT, magnetic resonance imaging (MRI), and 
somatostatin receptor scintigraphy (SRS). However, in the 
case of duodenal tumours, these methods are not as 
specific, considering that >75% of these tumours are 
under 1 cm [3]. Studies indicate that conventional 
imaging techniques detect <15% of tumours <1 cm [2], 
while SRS approximately 50% [15]. In order to identify 
the primary tumour, upper gastrointestinal endoscopy 
remains the most sensitive method, complemented with 
endoscopic ultrasound when possible, in order to assess 
local extension. For complete staging, spiral CT/MRI or 
SRS are recommended [3]. 
Usually, CrA and urinary 5-HIAA are measured in 
order to monitor carcinoid tumours. However, 5-HIAA is 
only specific to serotonin producing tumours, so that its 
measurement is useful only if carcinoid syndrome is 
present or if IHC staining detects the presence of 
serotonin [16]. Routine CrA measurement is 
recommended for all patients with NETs, regardless of 
their location [17]. High values appear in 56-100% of 
duodenal neuroendocrine tumours and they are correlated 
with the response to treatment [18]. 
The four main prognostic factors are: tumour stage, 
grade, resection margins, and chromogranin value. The 5-
year survival rate is 80-85% for localized disease, 65-75% 
for locally advanced disease, and 20-40% for metastatic 
disease [9].  
In order to determine tumour grade, the assessment of 
the mitotic count/10HPF and/or ki-67 index through IHC 
is necessary [14]. 
Usually, the treatment is curative. The endoscopic 
resection is considered sufficient for small tumours 
(<1cm). There is no consensus regarding intermediary 
tumours (1-2 cm), with some authors recommending 
surgery and others recommending endoscopic resection. 
More studies are needed in order to standardize treatment 
procedures [2,19]. Tumours larger than 2 cm are treated 
exclusively by surgery. In the case of metastatic disease, 
the resection of the primary tumour along with the local 
treatment of metastases (surgery, ablation) is common 
practice when possible [3,10]. Surgical excision is 
preferred for periampullary tumours, regardless of tumour 
size, as studies indicate that the presence of metastases is 
not correlated with the size of the primary tumour in these 
cases [20-22]. 
Systemic therapy applies only to the metastatic 
disease, when local treatment of the metastases is not 
possible. This includes somatostatin analogues and 
peptide receptor radionuclide therapy, while 
chemotherapy is used only for poorly differentiated 
tumours. Symptomatic treatment is recommended 
depending on the functional syndrome present in 
secreting tumours [23]. 
Highlights 
✓ Primary duodenal carcinoid tumours represent a 
heterogenous group of rare well-differentiated 
neuroendocrine tumours of the gastro-intestinal tract; 
✓ In the past years, there has been an increase in the 
incidence of these tumours, partly explained by more 
frequent detection by upper gastrointestinal 
endoscopy, which allows for an early diagnosis and a 
better prognosis; 
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Conclusions 
The incidence of duodenal carcinoid tumours has risen 
over time due to increased detection by upper 
gastrointestinal endoscopy, which allows for an early 
diagnosis, in an asymptomatic stage. Reporting these 
cases is important in order to establish the most 
appropriate management and follow-up for these patients, 
especially for those with tumours of 1-2 cm. 
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